CANDESARTAN CILEXETIL

Not available outside of the UK & Ireland.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Application

This pharmaceutical secondary standard can also be used as follows:Determination of candesartan cilexetil in tablet formulations by a UV/fluorescence spectrophotometric methodStudy of the release of candesartan cilexetil in tablet form by reversed-phase high-performance liquid chromatography (RP-HPLC)Simultaneous estimation of candesartan cilexetil and hydrochlorothiazide in pharmaceutical preparations using liquid chromatography in combination with photodiode array detector (DAD) and evaporative light scattering detector (ELSD)Spectroflourimetric determination of four angiotensin II receptor antagonists (AIIRA’;s) in their pure form as well as pharmaceutical formulations

Biochem/physiol Actions

Candesartan cilexetil is the prodrug form of the potent angiotensin II receptor antagonist, candesartan. The prodrug is cleaved by esterases within the intestine to liberate the active molecule.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAB8504 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.

General description

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.Candesartan cilexetil is an angiotensin II receptor antagonist used as a prodrug in the treatment of hypertension.